Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
Acquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer.
Guardado en:
Autores principales: | Fabin Dang, Li Nie, Jin Zhou, Kouhei Shimizu, Chen Chu, Zhong Wu, Anne Fassl, Shizhong Ke, Yuangao Wang, Jinfang Zhang, Tao Zhang, Zhenbo Tu, Hiroyuki Inuzuka, Piotr Sicinski, Adam J. Bass, Wenyi Wei |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/88efe8ceb62e4eb287e6888a694cafe6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Regulation of in vivo dynein force production by CDK5 and 14-3-3ε and KIAA0528
por: Dail E. Chapman, et al.
Publicado: (2019) -
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Jennifer Y. Ge, et al.
Publicado: (2020) -
Dataset of bond enthalpies (εAA, εAB, εBB) in 975 binary intermetallic compounds
por: Daniel Miracle, et al.
Publicado: (2021) -
Pure Micropapillary Rectal Carcinoma with CK7 and CK20 Coexpression and Loss of CDX2 Reactivity
por: Lino-Silva,Leonardo Saúl
Publicado: (2012) -
Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study
por: Qi Zheng, et al.
Publicado: (2021)